By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem to host microspheres peptide delivery webinar
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG is hosting a free online webinar on the emerging technologies of microspheres and nanoparticles for drug delivery of peptide-based active pharmaceutical ingredients.
The one hour webinar ‘Microspheres and Nanoparticles for Peptide Delivery’ will take place on January 19, 2021, starting at 1800hrs CET (UTC +1:00). Registration is free of charge (see Resources).
Microspheres and Nanoparticles for Peptide Delivery
Use of microspheres and nanoparticles are innovative responses to a central challenge of delivering peptides into the human organism – that poor peptide stability toward proteolytic enzymes and large molecule size together make for poor penetration into cells.
The webinar will explore how drug formulations based on microspheres and nanoparticles can encapsulate peptides for enhanced bioavailability and superior therapeutic efficacy.
The session will be moderated by Dr. Chris McGee, Senior Director of Business Development for Bachem Americas, who has played a leading role in communicating latest advances relating to peptide- and oligonucleotide-based new chemical entities (NCEs).
Scientific speaker will be Dr. Jyothi Thundimadathil, Associate Director at Bachem Americas Torrance facility, whose focus is NCE projects and CMC drug development covering peptides and related molecules.
The use of nanoparticles for delivering proteins and peptides are still in early stages of development and are rapidly maturing technologies. However, the online session will examine various case studies where microparticle formulation has been successfully applied in a number of commercial products containing peptides as APIs, where Bachem has been among the pioneers.
The webinar will go on to explore potential future benefits and challenges of microspheres and nanoparticles for peptide delivery.
The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com
About Jyothi Thundimadathil, Ph.D.
Dr. Jyothi Thundimadathil is an Associate Director at Bachem Americas Torrance facility. At Bachem he is focusing on NCE (New Chemical Entities) projects and CMC development during drug development program covering peptides and related molecules. He has more than 18 years of experience in peptide chemistry, previously serving in various roles such as Chemistry Director, Marketing Director and R&D Group Leader in peptide industry. After earning his Ph.D. in Applied Chemistry from CUSAT and NCL (India) he worked as post-doctoral fellow at Ben Gurion University (Israel), IUPUI (USA) and Purdue University (USA). He has published more than 60 papers, including peer-reviewed articles, reviews, invited articles in popular scientific magazines, technical information in encyclopedia of chemical reagents, book chapters and patents.
About Chris McGee, Ph.D.
Dr. Chris McGee is the Senior Director of Business Development for Bachem Americas. In this role, he and his field-based team of peptide experts represent the front line of communications related to the development and manufacturing of peptide and oligonucleotide based new chemical entities. Chris McGee has nearly a decade of experience at Bachem, and prior to this earned his Ph.D. in Organic Chemistry at the University of California, Irvine.